The postoperative pain management of stereotactic radiosurgery in patients with brain metastases from lung cancer

Clinical effects of the combination of morphine sulphate sustained-release tablets and Banxia Baizhu Tianma Decoction in the postoperative pain management of stereotactic radiosurgery in patients with brain metastases from lung cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN68431074

Enrollment

269

Registered

2025-03-07

Start date

2021-01-01

Completion date

Unknown

Last updated

2025-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative pain management of SRS in patients with brain metastases from lung cancer Cancer

Interventions

A total of 269 patients with brain metastasis of lung cancer admitted to the hospital from January 2021 to July 2024 were selected as the study subjects by convenience sampling method. They were rando

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Diagnosed with brain metastasis of lung cancer with clear pathological results and a score of =4 on the Pain Level Assessment Scale 2. Clear consciousness to cooperate with the assessment of pain level and quality of life 3. No allergy to the study drugs

Exclusion criteria

Exclusion criteria: 1. Allergic to the study drug 2. Drug addicts 3. Alcohol addicts 4. Respiratory depression 5. Psychiatric history

Design outcomes

Primary

Measure	Time frame
The following primary outcome measures were assessed at 2 weeks after the intervention: 1. The analgesic effect after intervention was divided into complete relief (CR, patients‘ pain was completely relieved after medication), partial relief (PR, patients’ pain was relieved after intervention and normal sleep was not affected), minor relief (MR, pain was improved after analgesia but it was not obvious, and patients' life and sleep were affected), and no relief (NR, analgesia was ineffective); the total effective rate = (CR+PR)/total number of cases × 100%. 2. The incidence of adverse reactions in the process of analgesia between the two groups of patients, mainly including constipation, nausea and vomiting, drowsiness, urine retention and so on 3. Quality of life assessed using the Quality of Life Scale for Oncology Patients	—

Measure

Time frame

The following primary outcome measures were assessed at 2 weeks after the intervention: 1. The analgesic effect after intervention was divided into complete relief (CR, patients‘ pain was completely relieved after medication), partial relief (PR, patients’ pain was relieved after intervention and normal sleep was not affected), minor relief (MR, pain was improved after analgesia but it was not obvious, and patients' life and sleep were affected), and no relief (NR, analgesia was ineffective); the total effective rate = (CR+PR)/total number of cases × 100%. 2. The incidence of adverse reactions in the process of analgesia between the two groups of patients, mainly including constipation, nausea and vomiting, drowsiness, urine retention and so on 3. Quality of life assessed using the Quality of Life Scale for Oncology Patients

—

Secondary

Measure	Time frame
There are no secondary outcome measures	—

Countries

China

Contacts

Public ContactLi Yang

yangli_hbzyy@163.com+86 (0)311-69095581

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026